JTE-907 is a pharmaceutical compound employed in scientific investigations, functioning as a discerning CB2 inverse agonist. This substance has demonstrated anti-inflammatory properties in animal experiments, with these effects believed to stem from an interplay between the CB2 receptor and IgE.

IUPAC name
CAS Number282089-49-0 
PubChem CID9867770
CompTox Dashboard (EPA)DTXSID001010010
ECHA InfoCard100.209.196
Chemical and physical data
Molar mass438.472 g·mol−1


1. What is JTE-907?

  • JTE-907 is a pharmaceutical compound primarily used in scientific research. It functions as a selective CB2 inverse agonist.

2. What Does “Selective CB2 Inverse Agonist” Mean?

  • Being a selective CB2 inverse agonist means that JTE-907 interacts with the CB2 receptor in a way that inhibits its activity. This selectivity is significant as it primarily affects the CB2 receptor without affecting the CB1 receptor, commonly associated with psychoactive effects.

3. What Are the Potential Medical Applications of JTE-907?

  • JTE-907 is primarily a research tool. Its anti-inflammatory effects, mediated through the CB2 receptor, make it potentially interesting for conditions involving inflammation, but further research is needed to explore its medical applications fully.

4. How Does JTE-907 Work in Anti-Inflammatory Research?

  • JTE-907’s anti-inflammatory effects are thought to be mediated through interactions between the CB2 receptor and IgE, an antibody related to allergic and inflammatory responses. This interaction may contribute to its anti-inflammatory properties in animal studies.

5. Is JTE-907 Available for Personal Use or Prescription?

  • JTE-907 is typically not available for personal use or prescription. It is primarily used as a research tool and may not be approved for human use due to its experimental nature.

6. Are There Any Known Side Effects of JTE-907?

  • The specific side effects of JTE-907 may not be well-documented as it is primarily a research compound. If considered for potential medical use in the future, thorough clinical studies would be required to assess its safety profile.

7. Where Can I Find More Information About JTE-907?

  • To learn more about JTE-907, you can refer to scientific literature research publications or consult with experts in the field. Remember that it is primarily a research compound, and its availability for general information may be limited.

8. Can JTE-907 Have Psychoactive Effects?

  • JTE-907 is primarily designed as a selective CB2 inverse agonist, and its effects are not typically associated with the psychoactive properties often attributed to compounds acting on the CB1 receptor.

9. Is JTE-907 Legal?

  • The legal status of JTE-907 may vary by region and is often determined by its use and intended purpose. It is crucial to comply with local regulations when using JTE-907 in research or any other context.

10. What Are the Ongoing Research Areas Related to JTE-907?

  • Ongoing research may explore JTE-907’s potential applications in anti-inflammatory studies, allergic responses, and CB2 receptor modulation. Stay updated with scientific literature to learn about the latest findings and applications.


  1. Delve into the pharmacological world of JTE-907 with insights from Iwamura H, Suzuki H, Ueda Y, Kaya T, and Inaba T (February 2001). “Unraveling the Intrigues of JTE-907: A Novel Selective Ligand for the Cannabinoid CB2 Receptor.” Detailed in The Journal of Pharmacology and Experimental Therapeutics, 296(2), 420–5. PMID: 11160626.
  2. Explore the realm of 2-oxoquinoline derivatives and their connection to CB2 receptor inverse agonists in research by Raitio KH, Savinainen JR, Vepsäläinen J, Laitinen JT, Poso A, Järvinen T, and Nevalainen T (March 2006). “Synthesis and Structure-Activity Relationship Studies: Deciphering the Secrets of CB2 Receptor Inverse Agonists.” Presented in the Journal of Medicinal Chemistry, 49(6), 2022–7. doi:10.1021/jm050879z. PMID: 16539390.
  3. Journey through the role of JTE-907 and the CB2 receptor in addressing cutaneous inflammation in mice with findings from Ueda Y, Miyagawa N, Matsui T, Kaya T, and Iwamura H (September 2005). “Exploring the Impact of Cannabinoid CB2 Receptor Inverse Agonist JTE-907 in Cutaneous Inflammation.” Published in the European Journal of Pharmacology, 520(1–3), 164–71. doi:10.1016/j.ejphar.2005.08.013. PMID: 16153638.
  4. Uncover the connection between cannabinoid CB2 receptors and IgE-mediated triphasic cutaneous reactions in mice in the study by Ueda Y, Miyagawa N, and Wakitani K (January 2007). “Deciphering the Role of Cannabinoid CB2 Receptors in IgE-Mediated Cutaneous Reactions.” Highlighted in Life Sciences, 80(5), 414–9. doi:10.1016/j.lfs.2006.09.026. PMID: 17055000.

Leave a Comment

Your email address will not be published. Required fields are marked *